<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364753">
  <stage>Registered</stage>
  <submitdate>8/08/2013</submitdate>
  <approvaldate>13/08/2013</approvaldate>
  <actrnumber>ACTRN12613000904774</actrnumber>
  <trial_identification>
    <studytitle>Comparative study between cabergoline and intravenous calcium in the prevention of ovarian hyper stimulation in women with polycystic ovarian disease undergoing Intracytoplasmic sperm injection (ICSI ).</studytitle>
    <scientifictitle>Comparative study between cabergoline and intravenous calcium in the prevention of ovarian hyper stimulation in women with polycystic ovarian disease undergoing  ICSI .</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ElKattan Protocol 100
Issuing authority ,Cairo University</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>subfertility
</healthcondition>
    <healthcondition>ovarian hyperstimulation</healthcondition>
    <healthcondition>Poly cystic ovarian disease</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fertility including in vitro fertilisation</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>0.5 mg oral Tablets cabergoline (Dostinex) daily for 8 days from the day of HCG injection. For once in the trial
To monitor the adherence to the medication we ask the patient for the drug tablet return.</interventions>
    <comparator>intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup.for once in the treatment cycle and each patient will undergo one treatment cycle during the trial.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The Occurrence  of ovarian hyper stimulation which can be diagnosed clinically by patient symptoms accompanied by ultrasonography and laboratory investigation  </outcome>
      <timepoint>10 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The severity of ovarian hyper stimulation which is detected by the need for ascitic drainage and the need for hospitalisation </outcome>
      <timepoint>10 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>chemical pregnancy rate :Positive (serum BHCG) 14 days following Embryo transfer</outcome>
      <timepoint>10 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>clinical pregnancy rate: positive pregnancy test and positive fetal heart beat by ultrasound after 6 weeks gestaional age</outcome>
      <timepoint>10 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>miscarriage rate: diagnosed by ultrasound /clinically</outcome>
      <timepoint>10 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>ectopic rate :diagnosed by ultrasound /clinically</outcome>
      <timepoint>10 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-Subfertile women with polycystic ovarian disease
-serum FSH within normal limits( 1-12IU /l)
-at least 15 follicles or more ,more than 10 mm at the time of HCG administration</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-patients need coasting for high risk of OHSS.
-patients need cycle cancellation.
-severe male infertility requiring testicular sperm extraction.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Concealment is done by central randomisation by the computer .Entry of a womanâ€™s initials, ID number, and date of birth on to a dedicated computer on the clinic, automatically generated the allocation group together with a study number, which was then recorded on the outcome sheet. These data could, if necessary, be verified against the computer randomisation at a later time.</concealment>
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>False</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/07/2013</anticipatedstartdate>
    <actualstartdate>15/07/2013</actualstartdate>
    <anticipatedenddate>30/04/2014</anticipatedenddate>
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>Cairo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Eman Elkattan</primarysponsorname>
    <primarysponsoraddress>Cairo University Teaching Hospital
1.Kasr AlAini street,Cairo Egypt
Postcode:11562</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Eman Elkattan</fundingname>
      <fundingaddress>Cairo University Teaching Hospital
1.Kasr AlAini street,Cairo Egypt
Postcode:11562</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>we study novel approaches in the management of ovarian hyperstimulation in women suffering with Polycystic ovarian disease (PCO) and undergoing Intracytoplasmic sperm injection (ICSI).we compare the effect of intravenous calcium and oral cabergoline on the severity of ovarian hyperstimulation and outcome of ICSI as regard the pregnancy rate and miscarriage rate</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Cairo University </ethicname>
      <ethicaddress>1.Kasr AlAini street
Cairo,Egypt
Postcode:11562</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Eman Elkattan</name>
      <address>Cairo University
1.Kasr alAini street,Cairo,Egypt
Postcode:11562</address>
      <phone>+20  1222854159</phone>
      <fax />
      <email>emyelkattan@gmail.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Eman Elkattan</name>
      <address>Cairo University
1.Kasr alAini street,Cairo ,Egypt
Postcode:11562</address>
      <phone>+20 1222854159</phone>
      <fax />
      <email>emyelkattan@gmail.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Eman Elkattan</name>
      <address>Cairo University
1.Kasr alAini street,Cairo ,Egypt
Postcode:11562</address>
      <phone>+20 1222854159</phone>
      <fax />
      <email>emyelkattan@gmail.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Eman Elkattan</name>
      <address>1.Kasr alAini street,Cairo,Egypt</address>
      <phone>+20 1222854159</phone>
      <fax />
      <email>emyelkattan@gmail.com</email>
      <country>Egypt</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>